These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23931441)

  • 1. Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease.
    Martinez A; Perez DI; Gil C
    Curr Top Med Chem; 2013; 13(15):1808-19. PubMed ID: 23931441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
    Avila J; Wandosell F; Hernández F
    Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Glycogen Synthase Kinase 3 Inhibitors for Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Matsunaga S; Fujishiro H; Takechi H
    J Alzheimers Dis; 2019; 69(4):1031-1039. PubMed ID: 31156177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycogen synthase kinase-3 as drug target: from wallflower to center of attention.
    Van Wauwe J; Haefner B
    Drug News Perspect; 2003 Nov; 16(9):557-65. PubMed ID: 14702136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].
    Liu SN; Shen ZF
    Yao Xue Xue Bao; 2007 Dec; 42(12):1227-31. PubMed ID: 18338632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A unique type of GSK-3 inhibitor brings new opportunities to the clinic.
    Licht-Murava A; Paz R; Vaks L; Avrahami L; Plotkin B; Eisenstein M; Eldar-Finkelman H
    Sci Signal; 2016 Nov; 9(454):ra110. PubMed ID: 27902447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enantioselective synthesis of the novel chiral sulfoxide derivative as a glycogen synthase kinase 3beta inhibitor.
    Saitoh M; Kunitomo J; Kimura E; Yamano T; Itoh F; Kori M
    Chem Pharm Bull (Tokyo); 2010 Sep; 58(9):1252-4. PubMed ID: 20823611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GSK-3 inhibitors: discoveries and developments.
    Alonso M; Martinez A
    Curr Med Chem; 2004 Mar; 11(6):755-63. PubMed ID: 15032729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.
    Medina M; Avila J
    Curr Pharm Des; 2010; 16(25):2790-8. PubMed ID: 20698823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).
    Palomo V; Martinez A
    Expert Opin Ther Pat; 2017 Jun; 27(6):657-666. PubMed ID: 27828716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural and synthetic bioactive inhibitors of glycogen synthase kinase.
    Khan I; Tantray MA; Alam MS; Hamid H
    Eur J Med Chem; 2017 Jan; 125():464-477. PubMed ID: 27689729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease.
    Huang HC; Klein PS
    Curr Drug Targets; 2006 Nov; 7(11):1389-97. PubMed ID: 17100579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lithium, a potential protective drug in Alzheimer's disease.
    Engel T; Goñi-Oliver P; Gómez de Barreda E; Lucas JJ; Hernández F; Avila J
    Neurodegener Dis; 2008; 5(3-4):247-9. PubMed ID: 18322403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newly developed glycogen synthase kinase-3 (GSK-3) inhibitors protect neuronal cells death in amyloid-beta induced cell model and in a transgenic mouse model of Alzheimer's disease.
    Noh MY; Chun K; Kang BY; Kim H; Park JS; Lee HC; Kim YH; Ku S; Kim SH
    Biochem Biophys Res Commun; 2013 May; 435(2):274-81. PubMed ID: 23632329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-modified glycogen synthase kinase-3β intervention by melatonin arrests the pathology and memory deficits in an Alzheimer's animal model.
    Peng CX; Hu J; Liu D; Hong XP; Wu YY; Zhu LQ; Wang JZ
    Neurobiol Aging; 2013 Jun; 34(6):1555-63. PubMed ID: 23402899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3.
    Koh SH; Noh MY; Kim SH
    Brain Res; 2008 Jan; 1188():254-62. PubMed ID: 18031715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GSK-3 inhibitors for Alzheimer's disease.
    Avila J; Hernández F
    Expert Rev Neurother; 2007 Nov; 7(11):1527-33. PubMed ID: 17997701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibitors of β-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates.
    Viayna E; Sabate R; Muñoz-Torrero D
    Curr Top Med Chem; 2013; 13(15):1820-42. PubMed ID: 23931440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GSK3 inhibitors and disease.
    Hernández F; Nido JD; Avila J; Villanueva N
    Mini Rev Med Chem; 2009 Aug; 9(9):1024-9. PubMed ID: 19689399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3β inhibitors for Alzheimer's disease.
    Fukunaga K; Sakai D; Watanabe K; Nakayama K; Kohara T; Tanaka H; Sunada S; Nabeno M; Okamoto M; Saito K; Eguchi J; Mori A; Tanaka S; Inazawa K; Horikawa T
    Bioorg Med Chem Lett; 2015 Mar; 25(5):1086-91. PubMed ID: 25655721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.